1 Here we describe 1-18, a new V(H)1-46-encoded CD4 bindin
2 Here, we describe 2 patients presenting with end-stage l
3 To address this,
here we describe a buffer modification workflow (BMW) in
4 Here we describe a Caenorhabditis elegans quiescent beha
5 Here we describe a catalytic, multicomponent method for
6 Here we describe a cellular O-glycome preparation strate
7 Here we describe a complementary target-engagement metho
8 Here we describe a crow-sized stem bird, Falcatakely for
9 Here we describe a dual genetic strategy in mice that re
10 Here we describe a family of potent imaging probes that
11 g a disease-causing nonsense point mutation,
here we describe a first-of-its-kind Cln3(Q352X) mouse m
12 Here we describe a general strategy for the directed evo
13 Here we describe a glucosamine-coated NISV, for blood-br
14 Here we describe a high-throughput analytical platform b
15 Here we describe a kethoxal-assisted single-stranded DNA
16 Here we describe a medulloblastoma model using Induced p
17 Here we describe a method for isolating human gut-associ
18 Here we describe a method that combines microfluidics, h
19 Here we describe a molecular switch involving a highly c
20 Here we describe a new fossil polychaete (bristle worm)
21 Here we describe a new method based on the application o
22 Here we describe a new series of LPA(1) agonists among w
23 Here we describe a new technique used to identify sex in
24 Here we describe a novel biochemical assay for the exami
25 Here we describe a novel interaction between Pol delta a
26 Here we describe a platform for efficient Cas12a gene ed
27 Here we describe a platform for measuring arrestin recru
28 Here we describe a platform for the detection of IgG ant
29 Here we describe a protocol that uses the ImageJ program
30 Here we describe a reference-free workflow for diploid d
31 Here we describe a regulation of Dicer expression in mon
32 Here we describe a robust genetic program that intrinsic
33 ation and growth of Clostridioides difficile
Here we describe a role for intestinal bile acids in dir
34 Here we describe a role for the innate immune-sensing mo
35 Here we describe a sampling approach derived from princi
36 Here we describe a second class of local excitatory inpu
37 Here we describe a strategy to address this problem base
38 Here we describe a strategy utilizing pan-family viral a
39 Here we describe a streamlined ACT protocol using Th17 c
40 Here we describe a subset of thymus recirculating IL18R(
41 Therefore,
here we describe a successful strategy that generated a
42 Here we describe a supramolecular material set and patte
43 Here we describe a systems biology workflow employing pl
44 Here, we describe a CD1a-bearing BDCA-2+CD123int DC subs
45 Here, we describe a city-wide SARS-CoV-2 nucleic acid sc
46 Here, we describe a cohort of adults with FASDs that had
47 Here, we describe a comprehensive protocol that details
48 Here, we describe a computational method HiNT (Hi-C for
49 Here, we describe a crystalline form of the cyclic GMP p
50 Here, we describe a deficiency of cilia and flagella ass
51 Here, we describe a detailed experimental protocol and a
52 Here, we describe a function for NEK10 in the regulation
53 Here, we describe a general approach for identifying spe
54 Here, we describe a genome-wide forward screen that show
55 Here, we describe a highly versatile in situ strategy fo
56 Here, we describe a lensless planar architecture, where
57 Here, we describe a mechanism by which the ARF tumor sup
58 Here, we describe a mechanism by which the innate immune
59 Here, we describe a methanotroph of the genera Methyloba
60 Here, we describe a methodology for targeted peptide qua
61 Here, we describe a morphogenetic movement in which the
62 Here, we describe a mouse model intended to reproduce he
63 Here, we describe a myeloid cell-selective NF-kappaB inh
64 Here, we describe a nanobody-based targeting approach fo
65 Here, we describe a new analytical platform that enables
66 Here, we describe a new approach by combining annular il
67 Here, we describe a new fossil specimen from Drimolen Ma
68 Here, we describe a new method for 3D motion estimation
69 Here, we describe a new resource, stdpopsim, that attemp
70 Here, we describe a new triplex RT-PCR assay to detect t
71 Here, we describe a novel application of biolayer interf
72 Here, we describe a novel brain tumor predisposition syn
73 Here, we describe a novel Brn3c(Cre) mouse allele genera
74 Here, we describe a novel formulation technology for bio
75 Here, we describe a novel framework to address this chal
76 Here, we describe a novel function of Rspo2 in FGF pathw
77 Here, we describe a novel mouse model that allows emiciz
78 Here, we describe a paradigm to control cancer growth th
79 Here, we describe a peroxisome-lysosome metabolic link t
80 Here, we describe a process to learn the constraints for
81 Here, we describe a protocol for operant social interact
82 Here, we describe a rare case of highly efficient near-c
83 Here, we describe a role for PCS in disease resistance a
84 Here, we describe a sensitive and robust LC-MS/MS assay
85 Here, we describe a serological enzyme-linked immunosorb
86 Here, we describe a severely autistic male patient carry
87 Here, we describe a simple platform for the expansion of
88 Here, we describe a single mechanism incorporating featu
89 Here, we describe a solution to this problem.
90 Here, we describe a statistical model approach to reliab
91 Here, we describe a stepwise engineering approach to gen
92 Here, we describe a strategy for cell- and polymerase-se
93 Here, we describe a super-sensitive AID system that inco
94 Here, we describe a system that combines a salicylic-ald
95 Here, we describe a three-stage protocol for reference-f
96 Here, we describe a total synthesis of PvD(1), the defen
97 Here, we describe a widespread mechanism promoting 3' US
98 Here, we describe a wireless device designed to be confo
99 Here, we described a dose-dependent effect of a unilater
100 Here, we described a new, comprehensive system of in sil
101 Here, we describe active surveillance efforts in live po
102 Here, we describe AlphaBeta, a computational method for
103 Here we describe an active learning approach to explore
104 Here we describe an aggressive in vivo model of Toll-lik
105 Here we describe an analysis method that provides data-d
106 Here we describe an approach that considers mechanical p
107 Here we describe an archaeological assemblage from Chagy
108 Here we describe an enzyme designed completely de novo t
109 Here we describe an ex vivo cultured human skin explant
110 Here we describe an experimental system to characterize
111 Here we describe an National Institutes of Health Common
112 Here we describe an ultrasensitive form of polymerizatio
113 Here, we describe an approach to large-scale nuclear arc
114 Here, we describe an approach to titrate expression of h
115 Here, we describe an approach utilizing synthetic DNA-en
116 Here, we describe an arrayed CRISPR screening method, Ge
117 Here, we describe an automation-enabled large-scale expe
118 Here, we describe an early ornithodiran (Kongonaphon kel
119 Here, we describe an early-onset neurodegenerative syndr
120 Here, we describe an easy and reproducible protocol for
121 Here, we describe an exquisitely tight interaction betwe
122 Here, we describe an external drainage technique for non
123 Here, we describe an imaging scheme that correlates cryo
124 Here, we describe an immortalized mouse neuronal astrocy
125 Here, we describe an inflammasome-independent pathway of
126 Here, we describe an integrated pipeline to define the i
127 Here, we describe an integrative structure determination
128 Here, we describe an optimization strategy for reducing
129 Here, we describe an optimized Cas9-AAV6-based genome ed
130 Here, we describe an unbiased genome-wide CRISPR-Cas9 kn
131 Here, we describe an unconventional interface between me
132 Here, we describe an unexpected role for the radial fibe
133 Here we describe and test a more ecologically-valid para
134 Here, we describe and characterize a potentially novel s
135 Here, we describe and experimentally demonstrate a strat
136 Here we describe barcodelet single-cell RNA sequencing (
137 Here we describe capillary microsampling with electrospr
138 Here we describe chemical epigenetic modifiers (CEMs) de
139 Here we describe '
circularization for high-throughput an
140 Here we describe CRISPR Guide RNA Assisted Reduction of
141 Here we describe CRISPR/dCas9-based enhancer-targeting e
142 Here, we describe CRISPR-based strategies to improve hum
143 Here, we describe CRISPR/Cas9-based editing of exon 1 of
144 Here we describe Cu-Al electrocatalysts, identified usin
145 Here, we describe currently available UPR modulating com
146 Here, we describe detailed procedures for generating gli
147 Here, we describe diseases known to be influenced by iCP
148 Here, we describe DNA enrichment of the zein gene from m
149 Here, we describe easily deployable hardware and softwar
150 Here, we describe evidence implicating WT1, the 11p15 lo
151 Here, we describe Fluopack screening as a novel platform
152 Here we describe for the first time the Macrocystis pyri
153 Here, we describe for the first time the feasibility of
154 Here, we describe fusion construct design and characteri
155 Here, we describe guidance for the verification of assay
156 Here we describe how selection for specific mutations th
157 Here we describe how to generate cancer cells with the a
158 Here we describe how unexpanded CGG repeats and their tr
159 Here, we describe how 3D particle sorting can enrich tar
160 cylindrus and Pseudo-nitzschia multistriata
Here, we describe how functional genomics and reverse ge
161 Here, we describe how genomics has been historically use
162 Here, we describe how members of the biomedical research
163 Here, we describe how regenerating biliary epithelial ce
164 Here, we describe how SRSF7 maintains its protein homeos
165 Here, we describe how the equilibrium concentrations of
166 Here, we describe how the use of Boolean networks (BNs)
167 Here, we describe how to adapt, configure and use an ine
168 Here, we describe how to apply the FitHiC2 protocol to t
169 Here, we describe how to use this method to label and/or
170 Here, we describe human antibody C585, isolated from a v
171 Here, we describe hypomorphic missense mutations of scos
172 Here we describe in situ laser-imaging technology(7) tha
173 Here, we describe in male crabs of this species a new gr
174 Here, we describe in situ genome sequencing (IGS), a met
175 Here, we describe in vivo conditional knockout analyses
176 Here, we describe key ADE mechanisms and discuss mitigat
177 Here we describe Kylinxia zhangi gen. et. sp. nov., a eu
178 Here we describe molecular characterization and drug tes
179 Here we describe multiple cryo-electron microscopy struc
180 Here, we describe novel M2e antibodies produced in mice
181 Here we describe NucleaSeq-nuclease digestion and deep s
182 Here, we describe one such signal that is provided by th
183 Here, we describe OpenMonkeyStudio, a deep learning-base
184 Here, we describe optimization of the imidazole-based ma
185 Here, we describe our extensive SAR studies exploring bo
186 Here we describe ped_draw a command line and web tool as
187 Here we describe progressive extensions to Cactus to cre
188 Here, we describe regulation of mRNA stability and P-bod
189 Here, we describe respiratory pacing using a closed-loop
190 Here, we describe roles for three metabolites-indole-3-e
191 Here we describe ruhugu virus and rustrela virus in Afri
192 Here we describe serial capture affinity purification (S
193 Here we describe several monoclonal antibodies that targ
194 Here we describe several structures of mouse and human F
195 Here, we describe small-molecule PAPD5 inhibitors that d
196 Here, we describe standardized computational pipelines s
197 Here we describe structures of the hexadecameric AHAS co
198 Here, we describe that sRNAs of the pathogen Hyaloperono
199 Here, we describe that the efficient DPC disassembly req
200 Here, we described that the complex Clb2-cyclin-dependen
201 Here we describe the ability of a binary thiol-amine sol
202 Here we describe the affinity maturation and humanizatio
203 Here we describe the binding mode of Staphylococcus aure
204 Here we describe the Brain Modeling ToolKit (BMTK), a so
205 Here we describe the breadth and depth of the biomedical
206 Here we describe the clinical translation of ONM-100, a
207 Here we describe the development of a candidate vaccine
208 Here we describe the development of a dual electrochemic
209 Here we describe the development of a long-term feeder-f
210 Here we describe the development of a pan-RAS biologic i
211 Here we describe the development of a series of potent,
212 Here we describe the development of the Angiosarcoma Pro
213 Here we describe the discovery and characterization of S
214 Here we describe the earliest-known mandibular fossil of
215 Here we describe the epidemiology of seasonal CoVs (sCoV
216 Here we describe the evolutionary dynamics of the adapta
217 Here we describe the fabrication of a 16-channel intrane
218 Here we describe the finding that heterochromatin and ge
219 Here we describe the first coprolites from the lagerstat
220 Here we describe the formation of an unexpected and uniq
221 Here we describe the full spectrum of the disease phenot
222 Here we describe the high-resolution X-ray structures of
223 Here we describe the identification of a novel series of
224 Here we describe the impact of induced Sbp2 deficiency i
225 Here we describe the implementation of strongly coordina
226 Here we describe the in planta use of carbon-based nanop
227 Here we describe the in vivo dynamics of hunger-promotin
228 Here we describe the integration of a proximity labeling
229 Here we describe the off-to-on photoswitching mechanism
230 Here we describe the preparation of stereoselectively de
231 Here we describe the production of a range of mini-spidr
232 Here we describe the rationale and ultimate design of a
233 Here we describe the selection and identification of DNA
234 Here we describe the stratigraphy, chronology, and mitoc
235 Here we describe the use of a promising radiation counte
236 Here we describe the use of discarded wound dressings as
237 Here we describe the use of Michler's hydrol blue (MHB)
238 Here we describe the visible-light-driven installation o
239 Here, we describe the 3.2 angstrom cryo-EM structure of
240 Here, we describe the agreed toolbox, which contains pro
241 Here, we describe the anticancer activity of novel conge
242 Here, we describe the characteristics of adults hospital
243 Here, we describe the characterization of a MINPP from t
244 Here, we describe the computational analyses leading to
245 Here, we describe the crystal structures of two distinct
246 Here, we describe the cytoskeletal determinant CcfM (cur
247 Here, we describe the design of a novel series of potent
248 Here, we describe the design of two-input AND, OR, NAND,
249 Here, we describe the development and performance of a p
250 Here, we describe the development and use of an assay to
251 Here, we describe the development of dual-color (DC) tsM
252 Here, we describe the development of the SpyCatcher immu
253 Here, we describe the different types of SSEs, how they
254 Here, we describe the establishment and use of a novel n
255 Here, we describe the extent of resistance of E. dermati
256 Here, we describe the extraordinary correspondence of th
257 Here, we describe the first paediatric cancer organoid b
258 Here, we describe the generation and characterization of
259 Here, we describe the generation and mapping of 55 new m
260 Here, we describe the HEDGES (Hash Encoded, Decoded by G
261 Here, we describe the identification, maturation, charac
262 Here, we describe the isolation of single-domain antibod
263 Here, we describe the key chromatin regulatory pathways
264 Here, we describe the long-term stability of a viral com
265 Here, we describe the mechanism responsible for the acti
266 Here, we describe the native state, observable intermedi
267 Here, we describe the neuroanatomical structure of this
268 Here, we describe the performance of a novel stimulus-re
269 Here, we describe the phenotype of 2 Cdk2 point mutants
270 Here, we describe the population structure of Ircinia ca
271 Here, we describe the potential of ionic liquids, in par
272 Here, we describe the potential underpinning of SAF micr
273 Here, we describe the procedures for xenograft cell tran
274 Here, we describe the protocols developed to produce mit
275 Here, we describe the purification and characterization
276 Here, we describe the regulation and dynamics of the exp
277 Here, we describe the results of our analysis of cellula
278 Here, we describe the results of the largest DNA methyla
279 Here, we describe the role of an uncharacterized N-termi
280 Here, we describe the spatial expression pattern of Notc
281 Here, we describe the structure-activity relationship (S
282 Here, we describe the synthesis and conformational analy
283 Here, we describe the synthesis of a new NDBF-based prot
284 Here, we describe the synthesis of a photocaged nucleoti
285 Here, we describe the thermodynamics of the formation of
286 Here, we describe the TIME of >6000 primarily pediatric
287 Here, we describe the two-phase process by which antigen
288 Here, we describe the UBPs developed by three research t
289 Methods:
Here, we describe the use of PARPi-FL, a fluorescent inh
290 Here, we describe the virological and immunological fact
291 Here, we described the case of a 60-year-old patient wit
292 Here, we described the discovery of a novel E3 ligase vo
293 Here we describe three potent inhibitors of SauCas9 that
294 Here we describe two protocols for the construction of r
295 Here, we describe two errors made in defining population
296 Here, we describe two MTBC strains isolated from patient
297 Here, we describe unexpected temporal compensatory respo
298 Here, we describe unique uncaging properties displayed b
299 Here, we describe unusual trace fossils found in margina
300 Here, we describe updates and recent expansions to CARD